Poor
Not Aligned
Patient Risk:
Medium
Summary
Most extracted claims are not supported by the specific provided label excerpts; however, the provided evaluation methodology is not fully verifiable because it relies on generic/insufficient citations and does not show the actual label text for confirming absence. This prevents a reliable on-label alignment assessment for each claim.
Category Scores
Accurate Statements
LYRICA may cause dizziness and somnolence.
Supported by 5.5 Dizziness and Somnolence: 'LYRICA may cause dizziness and somnolence.'
Unsupported Statements
Grapefruit and its juice may interact with Lyrica and may increase the medication's levels in the body.
No grapefruit-specific interaction or pregabalin level increase is shown in the provided label excerpts. The provided 7 section excerpt states pharmacokinetic interactions are unlikely but does not mention grapefruit.
Consuming grapefruit or grapefruit juice while taking Lyrica may increase the risk of side effects such as dizziness, drowsiness, and coordination problems.
No grapefruit-specific linkage to these adverse effects is present in the provided label excerpts.
Alcohol consumption can exacerbate the sedative effects of Lyrica.
No alcohol-specific interaction statement is present in the provided label excerpts.
Alcohol with Lyrica may increase the risk of dizziness, drowsiness, and impaired motor functions.
While impairment from dizziness/somnolence is referenced generally, no alcohol-specific augmentation language is provided in the excerpts.
High caffeine intake may interact with Lyrica and increase the risk of side effects.
No caffeine interaction is present in the provided label excerpts.
High doses of vitamin D may interact with Lyrica and may affect its efficacy.
No vitamin D interaction or efficacy effect is present in the provided label excerpts.
High doses of omega-3 fatty acids may increase the risk of bleeding while taking Lyrica.
No omega-3 interaction or bleeding risk is present in the provided label excerpts.
Spicy foods may exacerbate stomach issues or nausea associated with Lyrica.
Although nausea is mentioned in postmarketing experience, no food-type (spicy) guidance or interaction is provided in the excerpts.
High-sodium foods may worsen fluid retention and swelling associated with Lyrica.
Peripheral edema is discussed, but no sodium/food restriction or sodium-specific worsening guidance is present in the provided excerpts.
Contradictions
Important Omissions
Boxed warnings/contraindications and other safety statements were not assessed because the prompt-provided evaluation does not include the relevant label text sections for those topics.
Importance:
Moderate
The evaluation repeatedly treats claims as 'absent from the label' without presenting verbatim label text demonstrating absence for grapefruit/alcohol/caffeine/vitamin D/omega-3/food-type interactions; this limits confidence in the absence determination.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several extracted claims assert specific interaction effects (e.g., grapefruit increasing drug levels; alcohol increasing impairment risk; omega-3 increasing bleeding risk) that are not supported by the provided label excerpts. This creates risk of disseminating incorrect interaction guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Key interaction claims (grapefruit, alcohol, caffeine, vitamin D, omega-3, and food-type effects) are not supported by the provided label excerpts; the evaluation also lacks verifiable, verbatim label text for proving absence.
Suggested Improvement
Limit claims to what is explicitly supported in the provided label text. If assessing 'absence from label,' provide the specific verbatim label language (or additional relevant sections) that definitively confirm lack of the stated interaction.